Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Tango Therapeutics Inc. — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $63.01 (market cap $78.49B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 20.9× Tango Therapeutics Inc.'s market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.38% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 108 Days and Tango Therapeutics Inc. for 0 Days on average.
| MDLZ | TNGX | |
|---|---|---|
Market Cap | $78.49B | $3.75B |
Volume | 7,021,971 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $32.90 |
52-Week Low | $51.51 | $7.50 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $98.84B | $2.77B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $62.57, up 1.26% with strong technical momentum and bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54B in 2025, though net margins compressed to 6.36% from previous highs. Analyst consensus remains strongly bullish with a $70.29 price target, supported by recent dividend increases and strategic expansions.
MDLZ offers stable growth with defensive characteristics amid market volatility. Key opportunities include margin recovery from productivity gains and emerging market expansion. Risks include persistent cocoa cost pressures and competitive snack category dynamics. The stock presents a compelling risk-reward profile for long-term investors seeking quality consumer staples exposure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
